GLUE vs. MGX, STRO, CHRS, PSTX, AGEN, ZURA, CMPX, ABOS, ADAP, and IVVD
Should you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Metagenomi (MGX), Sutro Biopharma (STRO), Coherus BioSciences (CHRS), Poseida Therapeutics (PSTX), Agenus (AGEN), Zura Bio (ZURA), Compass Therapeutics (CMPX), Acumen Pharmaceuticals (ABOS), Adaptimmune Therapeutics (ADAP), and Invivyd (IVVD). These companies are all part of the "biological products, except diagnostic" industry.
Monte Rosa Therapeutics (NASDAQ:GLUE) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership.
Monte Rosa Therapeutics and Metagenomi both received 9 outperform votes by MarketBeat users. However, 90.00% of users gave Metagenomi an outperform vote while only 37.50% of users gave Monte Rosa Therapeutics an outperform vote.
In the previous week, Metagenomi had 14 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 17 mentions for Metagenomi and 3 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.00 beat Metagenomi's score of -0.32 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.
Monte Rosa Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 111.54%. Metagenomi has a consensus price target of $17.83, indicating a potential upside of 154.76%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts plainly believe Metagenomi is more favorable than Monte Rosa Therapeutics.
Metagenomi's return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.
80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 5.3% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Metagenomi has higher revenue and earnings than Monte Rosa Therapeutics.
Summary
Metagenomi beats Monte Rosa Therapeutics on 9 of the 12 factors compared between the two stocks.
Get Monte Rosa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monte Rosa Therapeutics Competitors List
Related Companies and Tools
